State Medicaid programs will also have access to these medications at these prices. CNBC reported on November 6, 2025, that Medicare will start covering obesity drugs for some patients for the first time starting mid-2026, a long-awaited move that could broaden the market for the medicines and spur more private insurers to cover them. A senior administration official explained the rationale to CNBC: We are constraining the access for patients that will benefit clinically from it, weve worked very hard to strike a balance between broad access that just makes sure to capture patients that will benefit clinically. Documentation of these qualifying conditions will be essential for coverage approval
All volunteers had to abstain from other medications, supplementary vitamins, and alcohol intake for 2 weeks prior to enrollment and throughout the study
Individual allergic reactions may occur
You find yourself anxious about drinking because of unpredictable effects
Reaching Maintenance Dose: Long-Term Side Effect Profile Once you reach your optimal maintenance dose, typically between 10mg and 15mg, side effects usually stabilise
How common is semaglutide bloating and what the clinical data actually shows Numbers matter here because they set expectations